Oct 25 (Reuters) - India's Jubilant Pharmova JUBA.NS
reported a 64.5% rise in second-quarter profit on Friday, driven
by a strong demand for its drugs with radioactive ingredients,
used to treat cancer and other diseases.
Consolidated net profit rose to 1.03 billion rupees (about
$12 million) in the quarter ended Sept. 30 from 625 million
rupees a year ago.
Revenue rose 4.5% to 17.42 billion rupees, lifted by the
radiopharma segment's nearly 11% growth in this quarter.
The drugmaker, which manufactures and supplies
radiopharmaceuticals used to diagnose and treat cancer and other
diseases such as hyperthyroidism and lung diseases, has a
network of 52 radio-pharmacies in the United States.
This business accounted for nearly 50% of the total revenue.
Revenue from its contract manufacturing segment, the firm's
second biggest segment which makes sterile injectables, rose 5%.
Shares of the company turned positive after results and rose
as much as 2% before paring most gains to trade flat.
($1 = 84.0540 Indian rupees)
(Reporting by Kashish Tandon in Bengaluru; Editing by Sumana
Nandy)
((mailto:Kashish.Tandon@thomsonreuters.com; 8800437922;))